Royalty Pharma (RPRX) FCF Payout Ratio Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) FCF Payout Ratio Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn | 0.27% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | - |
| 10 | Royalty Pharma | 25.70 Bn | 25.09 Bn | - | 65.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.80% |
| Dec 31, 2025 | 241.26% |
| Sep 30, 2025 | -109.29% |
| Jun 30, 2025 | 124.42% |
| Mar 31, 2025 | 63.52% |
| Dec 31, 2024 | 219.81% |
| Sep 30, 2024 | -124.85% |
| Jun 30, 2024 | -881.20% |
| Mar 31, 2024 | -28.40% |
| Dec 31, 2023 | -202.85% |
| Sep 30, 2023 | 611.91% |
| Jun 30, 2023 | -41.03% |
| Mar 31, 2023 | 3.03% |
| Dec 31, 2022 | 114.34% |
| Sep 30, 2022 | 65.69% |
| Jun 30, 2022 | -70.48% |
| Mar 31, 2022 | -98.63% |
| Dec 31, 2021 | -160.27% |
| Sep 30, 2021 | 63.46% |
| Jun 30, 2021 | -96.44% |